Revolution Medicines (RVMD) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $177.96, -5.97% vs the prior close of $189.26.
- Volume 2.97M shares, 1.5x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
RVMD slides 6.0% to $177.96, a 3-month low. Closed at $177.96, -5.97% vs the prior close of $189.26. Day range $175.91–$189.68, opened at $189.68.
RVMD daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — RVMD slides 6.0% to $177.96, a 3-month low
- Closed at $177.96, -5.97% vs the prior close of $189.26. Day range $175.91–$189.68, opened at $189.68.
- Volume was 2.97M shares, 1.5x its 50-day average of 1.98M.
- Price is -12.4% vs its 50-day average ($203.12) and +17.4% vs its 200-day average ($151.62).
- 52-week range $49.05–$224.31; today's close sits at 74% of that range, 20.7% below the 52-week high.
Oct 15, 2026 — RVMD dips 2.2% to $189.26
- Closed at $189.26, -2.20% vs the prior close of $193.52. Day range $189.14–$195.94, opened at $193.31.
- Volume was 1.57M shares, 0.8x its 50-day average of 1.99M.
- Price is -7.0% vs its 50-day average ($203.52) and +25.2% vs its 200-day average ($151.13).
- 52-week range $47.45–$224.31; today's close sits at 80% of that range, 15.6% below the 52-week high.
Oct 14, 2026 — RVMD rises 2.7% to $193.52
- Closed at $193.52, +2.70% vs the prior close of $188.44. Day range $185.88–$197.00, opened at $186.84.
- Volume was 2.46M shares, 1.2x its 50-day average of 1.97M.
- Price is -5.0% vs its 50-day average ($203.68) and +28.5% vs its 200-day average ($150.58).
- 52-week range $47.45–$224.31; today's close sits at 83% of that range, 13.7% below the 52-week high.
Oct 13, 2026 — RVMD dips 2.8% to $188.44
- Closed at $188.44, -2.84% vs the prior close of $193.95. Day range $187.14–$193.61, opened at $191.57.
- Volume was 2.94M shares, 1.5x its 50-day average of 1.95M.
- Price is -7.5% vs its 50-day average ($203.68) and +25.6% vs its 200-day average ($150.02).
- 52-week range $47.45–$224.31; today's close sits at 80% of that range, 16.0% below the 52-week high.
- SEC filings that day: 8-K.
Oct 12, 2026 — RVMD rises 2.2% to $193.95
- Closed at $193.95, +2.21% vs the prior close of $189.76. Day range $184.76–$194.26, opened at $187.79.
- Volume was 1.67M shares, 0.9x its 50-day average of 1.95M.
- Price is -4.7% vs its 50-day average ($203.56) and +29.7% vs its 200-day average ($149.48).
- 52-week range $47.28–$224.31; today's close sits at 83% of that range, 13.5% below the 52-week high.
Oct 9, 2026 — RVMD rises 0.9% to $189.76
- Closed at $189.76, +0.87% vs the prior close of $188.12. Day range $184.37–$193.50, opened at $186.01.
- Volume was 2.21M shares, 1.1x its 50-day average of 1.94M.
- Price is -6.7% vs its 50-day average ($203.43) and +27.4% vs its 200-day average ($148.91).
- 52-week range $47.28–$224.31; today's close sits at 80% of that range, 15.4% below the 52-week high.
Oct 8, 2026 — RVMD slides 6.3% to $188.12, a 1-month low on 2.6x normal volume
- Closed at $188.12, -6.35% vs the prior close of $200.87. Day range $180.49–$199.64, opened at $198.51.
- Volume was 4.86M shares, 2.6x its 50-day average of 1.89M — unusually heavy trading.
- Price is -7.5% vs its 50-day average ($203.48) and +26.8% vs its 200-day average ($148.37).
- 52-week range $46.16–$224.31; today's close sits at 80% of that range, 16.1% below the 52-week high.
Oct 7, 2026 — RVMD rises 0.5% to $200.87
- Closed at $200.87, +0.50% vs the prior close of $199.87. Day range $196.25–$203.50, opened at $198.18.
- Volume was 1.18M shares, 0.6x its 50-day average of 1.91M.
- Price is -1.2% vs its 50-day average ($203.33) and +35.9% vs its 200-day average ($147.82).
- 52-week range $45.80–$224.31; today's close sits at 87% of that range, 10.4% below the 52-week high.
Oct 6, 2026 — RVMD slides 3.8% to $199.87
- Closed at $199.87, -3.76% vs the prior close of $207.68. Day range $195.00–$208.57, opened at $208.57.
- Volume was 1.63M shares, 0.9x its 50-day average of 1.91M.
- Price is -1.5% vs its 50-day average ($202.99) and +35.8% vs its 200-day average ($147.20).
- 52-week range $45.80–$224.31; today's close sits at 86% of that range, 10.9% below the 52-week high.
Oct 5, 2026 — RVMD rises 0.5% to $207.68, 5 up days in a row
- Closed at $207.68, +0.50% vs the prior close of $206.64. Day range $201.83–$210.27, opened at $207.68.
- Volume was 1.42M shares, 0.7x its 50-day average of 1.91M.
- Price is +2.4% vs its 50-day average ($202.76) and +41.7% vs its 200-day average ($146.58).
- 52-week range $45.72–$224.31; today's close sits at 91% of that range, 7.4% below the 52-week high.
- That makes 5 straight gains.
Oct 2, 2026 — RVMD rises 0.4% to $206.64, 4 up days in a row
- Closed at $206.64, +0.36% vs the prior close of $205.89. Day range $204.07–$208.82, opened at $205.89.
- Volume was 1.57M shares, 0.8x its 50-day average of 1.92M.
- Price is +2.1% vs its 50-day average ($202.39) and +41.6% vs its 200-day average ($145.93).
- 52-week range $45.60–$224.31; today's close sits at 90% of that range, 7.9% below the 52-week high.
- That makes 4 straight gains.
RVMD latest news & SEC filings
Every SEC filing by or about RVMD in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 8.01 — Reported other events the company considers important.
Oct 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Sandler Alan B. converted options/RSUs into 6,000 shares at $58.84 (≈$353.04K) on Sep 29, 2026; now holds 58,868
- Sandler Alan B. sold 2,200 shares at $200.82 (≈$441.80K) on Sep 29, 2026; now holds 56,668
- Sandler Alan B. sold 1,609 shares at $201.72 (≈$324.57K) on Sep 29, 2026; now holds 55,059
- Sandler Alan B. sold 1,000 shares at $202.81 (≈$202.81K) on Sep 29, 2026; now holds 54,059
- Sandler Alan B. sold 1,199 shares at $203.91 (≈$244.48K) on Sep 29, 2026; now holds 52,860
- Sandler Alan B. sold 301 shares at $204.72 (≈$61.62K) on Sep 29, 2026; now holds 52,559
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cislini Jeff sold 765 shares at $207.32 (≈$158.60K) on Sep 25, 2026; now holds 51,776
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 29, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mancini Anthony sold 587 shares at $200.00 (≈$117.40K) on Sep 24, 2026; now holds 39,765
- Mancini Anthony converted options/RSUs into 3,121 shares at $33.62 (≈$104.93K) on Sep 25, 2026; now holds 42,886
- Mancini Anthony sold 3,121 shares at $200.54 (≈$625.89K) on Sep 25, 2026; now holds 39,765
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 25, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Anderson Elizabeth M converted options/RSUs into 5,070 shares at $1.12 (≈$5.68K) on Sep 22, 2026; now holds 14,476
- Anderson Elizabeth M sold 910 shares at $191.85 (≈$174.59K) on Sep 22, 2026; now holds 13,566
- Anderson Elizabeth M sold 4,985 shares at $192.54 (≈$959.81K) on Sep 22, 2026; now holds 8,581
- Anderson Elizabeth M sold 2,648 shares at $193.44 (≈$512.23K) on Sep 22, 2026; now holds 5,933
- Anderson Elizabeth M sold 1,500 shares at $194.59 (≈$291.88K) on Sep 22, 2026; now holds 4,433
- Anderson Elizabeth M sold 100 shares at $195.15 (≈$19.52K) on Sep 22, 2026; now holds 4,333
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
Aug 26, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$644.37M (prior year -$247.79M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$3.06 (prior year -$1.31) (loss widened vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 29, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade RVMD
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Feb 25, 2026, Nov 5, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.07% (largest 6.3%).
- Liquidity: about 2.22M shares (≈$395.55M) trade per day on average.
- 52-week position: $177.96 vs a range of $49.05–$224.31 (74% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Jeff Cislini sold 765 shares on Sep 25, 2026.
- Latest filings: 8-K Oct 13, 2026; 8-K Sep 1, 2026; 8-K Aug 26, 2026.
- Share count: 214.34M shares outstanding (Jul 31, 2026), +14.7% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
RVMD market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 189.68 | 189.68 | 175.91 | 177.96 | 2.97M |
| Oct 15, 2026 | 193.31 | 195.94 | 189.14 | 189.26 | 1.57M |
| Oct 14, 2026 | 186.84 | 197.00 | 185.88 | 193.52 | 2.46M |
| Oct 13, 2026 | 191.57 | 193.61 | 187.14 | 188.44 | 2.94M |
| Oct 12, 2026 | 187.79 | 194.26 | 184.76 | 193.95 | 1.67M |
| Oct 9, 2026 | 186.01 | 193.50 | 184.37 | 189.76 | 2.21M |
| Oct 8, 2026 | 198.51 | 199.64 | 180.49 | 188.12 | 4.86M |
| Oct 7, 2026 | 198.18 | 203.50 | 196.25 | 200.87 | 1.18M |
| Oct 6, 2026 | 208.57 | 208.57 | 195.00 | 199.87 | 1.63M |
| Oct 5, 2026 | 207.68 | 210.27 | 201.83 | 207.68 | 1.42M |
| Oct 2, 2026 | 205.89 | 208.82 | 204.07 | 206.64 | 1.57M |
| Oct 1, 2026 | 204.00 | 210.88 | 203.26 | 205.89 | 2.10M |
| Sep 30, 2026 | 205.48 | 209.79 | 203.00 | 205.26 | 1.84M |
| Sep 29, 2026 | 201.41 | 204.96 | 200.00 | 204.48 | 1.72M |
| Sep 28, 2026 | 203.97 | 204.98 | 200.98 | 201.74 | 1.81M |
| Sep 25, 2026 | 200.54 | 211.51 | 197.97 | 204.97 | 2.52M |
| Sep 24, 2026 | 190.15 | 201.28 | 189.84 | 199.86 | 4.06M |
| Sep 23, 2026 | 193.30 | 196.71 | 189.05 | 190.74 | 2.12M |
| Sep 22, 2026 | 191.56 | 195.28 | 191.22 | 192.86 | 1.88M |
| Sep 21, 2026 | 192.60 | 194.93 | 190.57 | 192.76 | 1.89M |
About Revolution Medicines
Revolution Medicines (RVMD) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in REDWOOD CITY, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1628171.
RVMD board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Elizabeth M Anderson | Director | Sep 24, 2026 |
| Flavia Borellini | Director | Jun 23, 2026 |
| Alexis Borisy | Director | Jun 23, 2026 |
| Frank Clyburn | Director | Jun 23, 2026 |
| Mark A Goldsmith | See Remarks | Sep 18, 2026 |
| Sandra Horning | Director | Jun 23, 2026 |
| Lorence H. Kim | Director | Sep 10, 2026 |
| Sushil Patel | Director | Jul 1, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Jack Anders | Chief Financial Officer | Sep 18, 2026 |
| Jeff Cislini | SVP & General Counsel | Sep 29, 2026 |
| Mark A Goldsmith | See Remarks | Sep 18, 2026 |
| Margaret A Horn | Chief Operating Officer | Sep 18, 2026 |
| Stephen Michael Kelsey | See Remarks | Sep 18, 2026 |
| Anthony Mancini | See Remarks | Sep 28, 2026 |
| Alan B. Sandler | Chief Development Officer | Sep 18, 2026 |
| Xiaolin Wang | See Remarks | Mar 19, 2026 |
| Lin Wei | Chief Medical Officer | Mar 19, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 25, 2026 | Jeff Cislini | Sale | 765 | $207.32 |
| Sep 25, 2026 | Jeff Cislini | Sale | 765 | $207.32 |
| Sep 25, 2026 | Jeff Cislini | Sale | 765 | $207.32 |
| Sep 25, 2026 | Jeff Cislini | Sale | 765 | $207.32 |
| Sep 25, 2026 | Anthony Mancini | Sale | 3,121 | $200.54 |
| Sep 25, 2026 | Anthony Mancini | Sale | 3,121 | $200.54 |
| Sep 25, 2026 | Anthony Mancini | Sale | 3,121 | $200.54 |
| Sep 25, 2026 | Anthony Mancini | Sale | 3,121 | $200.54 |
| Sep 24, 2026 | Anthony Mancini | Sale | 587 | $200.00 |
| Sep 24, 2026 | Anthony Mancini | Sale | 587 | $200.00 |
| Sep 24, 2026 | Anthony Mancini | Sale | 587 | $200.00 |
| Sep 24, 2026 | Anthony Mancini | Sale | 587 | $200.00 |
| Sep 22, 2026 | Elizabeth M Anderson | Sale | 100 | $195.15 |
| Sep 22, 2026 | Elizabeth M Anderson | Sale | 2,648 | $193.44 |
| Sep 22, 2026 | Elizabeth M Anderson | Sale | 4,985 | $192.54 |
RVMD financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $0 | $-1.13B | -5.95 | $-897.74M |
| Dec 31, 2024 | $0 | $-600.09M | -3.58 | $-557.44M |
| Dec 31, 2023 | $11.58M | $-436.37M | -3.86 | $-350.57M |
| Dec 31, 2022 | $35.38M | $-248.71M | -3.08 | $-224.40M |
| Dec 31, 2021 | $29.39M | $-187.09M | -2.57 | $-147.18M |
Latest balance sheet: total assets $4.32B, total liabilities $1.72B, cash $815.43M (as of Jun 30, 2026).
RVMD earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $197.30 |
| May 6, 2026 | 8-K Item 2.02 (results) | $151.07 |
| Feb 25, 2026 | 8-K Item 2.02 (results) | $103.24 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $59.34 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $36.67 |
| May 7, 2025 | 8-K Item 2.02 (results) | $37.66 |
| Feb 26, 2025 | 8-K Item 2.02 (results) | $40.50 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $59.42 |
| Aug 7, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Feb 26, 2024 | 8-K Item 2.02 (results) | — |
| Jan 9, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)Repligen (RGEN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on RVMD
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.